The Immunochemistry Analyzer Market Size is expected to register a CAGR of 16% during the forecast period, up from US$ 14.2 Bn in 2021, to reach a valuation of US$ 72.69 Bn by 2032.
Request a Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-866
Due to increased demand for immunochemistry analyzers to diagnose and identify microorganism-based illnesses, the Immunochemistry analyzer market is expected to show promising growth prospects during the forecasted period.
Immunochemistry analyzer sales are expected to increase due to increased demand for immunochemistry analyzers to diagnose and detect microorganism-based illnesses and disorders, as well as the growing need for managing and suppressing the incidence of major diseases.
This is propelling the immunochemistry analyzers market forward.
Immunochemistry analyzers run tests on patient samples automatically to detect any number of biologically active substances. Another factor driving immunochemistry analyzer demand is its application in infectious disease testing, cancer, cardiac, and autoimmune diseases.
The rise in demand for improved diagnostic equipment, as well as the rise in automation and integration trends, has resulted in the creation of novel products, which are likely to provide substantial growth opportunities for the immunochemistry analyzers market from 2022 to 2032.
What are the Growth Propellers to the Immunochemistry Analyzer Market Share?
One of the major factors driving the growth and demand for immunochemistry analyzers is the increased demand for diagnosing and identifying microorganism-based illnesses.
Furthermore, the rapid rise in the need for controlling and suppressing the occurrence of significant diseases, as well as the rising demand for immunochemistry analyzers the incidence of chronic disease conditions such as cancer and autoimmune disorders, are expected to drive growth in the global immunochemistry analyzers market from 2022 to 2032.
Similarly, the increasing elderly population, rapid changes in lifestyle, and increased smoking and drinking habits are expected to drive immunochemistry analyzer market growth.
Furthermore, the increased demand for automated and portable immunochemistry systems is expected to drive the immunochemistry analyzer market.
Contact our Market Research Specialist @ https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-866
Which Region holds the Highest Growth Potential in the Immunochemistry Analyzer Market?
North America led the immunochemistry analyzers market with a 38% revenue share, followed by Europe.
The commercial availability of sophisticated technology items and the high adoption rate of these products were primarily responsible for North America’s largest immunochemistry analyzer market share. Furthermore, major players in the country generate revenue for the US.
The Asia Pacific region immunochemistry analyzers market is expected to grow rapidly between 2022 and 2032, at a CAGR of 7.0%. Japan is a leader in technological advancements and the increased use of immunochemistry analyzers for a variety of applications. Furthermore, China is a significant contributor to the growth of the immunochemistry analyzers market.
The region’s thriving medical tourism business is likely to stimulate demand for immunochemistry analyzers in countries such as Japan, China, Malaysia, Thailand, and India. The availability of trained Major pharmaceutical companies are relocating their manufacturing operations to Asia Pacific due to low-cost labour and modern manufacturing infrastructure.
As a result, the region’s constantly expanding number of industrial facilities is propelling the Asia Pacific immunochemistry analyzers market forward.
How is the Competitive Landscape in the Immunochemistry Analyzer Market?
Siemens, Abbott Diagnostics, Beckman Coulter, Ortho Clinical Diagnostics, Thermo Fisher Scientific Inc., and F. Hoffmann-La Roche Ltd. dominate the immunochemistry analyzer market.
Mesa Biotech, a private point-of-care molecular diagnostic startup, was purchased by Thermo Fisher Scientific Inc. in February 2021.
In January 2021, Abbott received the CE Mark for their Panbio COVID-19 Ag Rapid Test Device for the asymptomatic detection of the SARS-CoV-2 virus. It is also capable of self-swabbing.
Beckman Coulter, a Danaher (US) company, will launch the Access SARS-CoV-2 Antigen assay, the first high-quality and throughput test for COVID-19 antigen diagnosis, in the United States in December 2020.
Thermo Fisher Scientific will introduce its EliA SARS-CoV-2-Sp1 IgG test and OmniPATH COVID-19 Total Antibody ELISA test for the detection of COVID-19 antibodies in October 2020.
Key companies profiled
Siemens, Abbott Diagnostics, Beckman Coulter, Ortho Clinical Diagnostics, Thermo Fisher Scientific Inc. and F. Hoffmann-La Roche Ltd.
Customization scope
Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Key Segments
By Product Type:
- Chemiluminescence Immunoassay
- Immunofluorescence Analyzers
- Radioimmunoassay
- Enzyme-Linked Immunoassay
- Consumables and Accessories
By Application:
- Therapeutic Drug Monitoring
- Oncology
- Cardiology
- Allergy Testing
- AIDS
- Endocrinology
- Infectious Disease Testing
- Autoimmune Disease
- Others
Buy Now@ https://www.futuremarketinsights.com/checkout/866
About Future Market Insights (FMI)
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs